Business Wire

ALEPH-FARMS

3.11.2021 11:05:08 CET | Business Wire | Press release

Share
Aleph Farms Unveils Roadmap For Achieving Net Zero Carbon By 2025

Aleph Farms , the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced its detailed roadmap for achieving net zero carbon. In April 2020 , Aleph Farms first announced it would reach net zero within its operations by 2025, and throughout its entire supply chain by 2030. Today, Aleph Farms’ net zero carbon roadmap details its scope for achievement, strategic partnerships and the investments necessary to advance its environmental goals and business bottom line as the company delivers its quality cultivated beef steaks.

“The production of food is one of the largest sources of greenhouse gas emissions on the planet today, and a driving reason why Aleph Farms is making long-term sustainability a top priority,” said Dr. Lee Recht, VP sustainability at Aleph Farms. “Our roadmap represents significant research that will enable us to fulfill our commitment to total net zero within this decade and we strongly encourage other companies within the agrifood ecosystem to work to eliminate their carbon footprint as soon as possible.”

Aleph Farms’ roadmap to net zero carbon was created in partnership with Aimee Christensen, CEO of Christensen Global Strategies and a world-renowned expert in climate change and sustainability strategies. The roadmap to reduce the company’s carbon footprint includes optimized energy efficiency, transitioning renewable energy, offsetting and/or insetting unavoidable remaining emissions via reinvestment in decarbonizing Aleph Farms’ own production lines and supply chains.

“By building a company with a net zero mindset from nearly day one, Aleph Farms is pioneering the smart clean growth that all companies must take,” Christensen said. “By investing in energy efficiency and direct renewable energy supplies and similar strategies within its supply chain, Aleph Farms will benefit their bottom line now and even more in the future as carbon is priced around the world.”

As part of its roadmap, Aleph Farms has also signed a Memorandum of Understanding (MoU) with ENGIE Impact , the sustainability consulting arm of ENGIE . The two companies will work together to ensure Aleph Farms’ operations are net-zero compatible from the get-go, integrating energy efficiency, circularity in energy, as well as renewable energy and other strategic investments across Aleph’s production line and supply chains.

“We are delighted to work with Aleph Farms to support their net-zero strategy and vision to transform the meat industry,” said Nicolas Lefevre-Marton, Managing Director, EMEAI at ENGIE Impact. “We are deeply committed to helping bold organizations of all sizes around the world develop the right decarbonization goals, roadmaps and execution strategies to successfully achieve net-zero.”

In addition, Aleph Farms’ commitment to net zero carbon is being supported by a partnership with CE Delft , to analyze the life cycle impacts of Aleph Farms’ production line and supply chain, identifying hotspots and working to optimize the overall ecological footprint including carbon, water, waste and more. CE Delft recently conducted a study that found cultivated meat has the potential to reduce the carbon footprint of beef production by 92% when utilizing renewable sources of energy.

Aleph Farms is co-hosting an event alongside Food Tank at this year’s COP26 in Glasgow, Scotland on November 9, 2021. The panel, A New Approach to Meat , will discuss what it takes to change the production of animal protein and improve environmental impact while maintaining farmers' livelihoods and food security. The company’s white paper, An Inclusive Transition to a Sustainable and Resilient Meat Sector , highlights how transformational net zero carbon production systems can complement sustainable agricultural practices, supplying nutritional food to the growing population and strengthening global food security. To learn more about Aleph Farms' path to sustainability, please visit aleph-farms.com/sustainability .

About Aleph Farms

Aleph Farms grows beef steaks, from non-genetically engineered, non immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye